Last updated on February 2018

Leflunomide Versus Azathioprine for Maintenance Therapy of Lupus Nephritis


Brief description of study

Leflunomide versus Azathioprine for Maintenance Therapy of Lupus Nephritis

Detailed Study Description

Proliferative glomerulonephritis is a common and severe manifestation of systemic lupus erythematosus (SLE) that usually requires intensive therapy with high doses of glucocorticosteroids and cytotoxic drugs, such as intravenous (IV) cyclophosphamide (CYC). The objective of this Trial is to compare leflunomide (LEF) and azathioprine (AZA), in terms of efficacy and toxicity, as remission-maintaining treatment of proliferative lupus glomerulonephritis, after a remission-inducing therapy with a short-course IV CYC regimen. The hypothesis of this trial is that LEF is non-inferior to AZA.

Clinical Study Identifier: NCT01172002

Contact Investigators or Research Sites near you

Start Over

Bao Chun De

RenJi Hospital
ShangHai, China
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.